The financing alleviates near-term liquidity concerns and funds the critical ELPIS II readout, but the high potential dilution and milestone dependency introduce risk. Traders should monitor the Q3 2026 data readout and any updates on PRV eligibility or second tranche triggers.
Price Chart
Executive Summary
Longeveron (LGVN) closed the first tranche of a $30 million private placement, raising $15 million upfront through a mix of common and convertible preferred stock issued at $0.52 per share. Proceeds extend the company's cash runway into Q4 2026, covering the pivotal Phase 2b ELPIS II trial readout for HLHS in Q3 2026. An additional $15 million is contingent on clinical milestones and share price performance.
Key Financial Metrics
Key Facts
- Raised $15 million in initial tranche of private placement, with up to $15 million more contingent on milestones.
- Issued 6,013,384 Class A common shares and Series A Preferred Shares convertible into 22,832,770 common shares, all priced at $0.52 per share.
- Cash runway extended into Q4 2026, past the ELPIS II trial topline data readout in Q3 2026.
- Investors include Coastlands Capital, Janus Henderson Investors, Logos Capital, and Kalehua Capital.
- Investors receive 50% of proceeds from potential Rare Pediatric Disease Priority Review Voucher (PRV) sale.
- H.C. Wainwright & Co. acted as exclusive placement agent; registration rights granted for resale.
Financial Impact
$15 million immediate capital raise, with $15 million milestone-dependent. Total potential dilution from conversion: ~28.8 million new shares (478% of current ~6M float).
Risk Factors
- High dilution: conversion of preferred shares would increase share count by ~478%.
- Second tranche is not guaranteed — dependent on clinical trial results and share price.
- No assurance of PRV issuance or monetization, which underpins part of the investor return structure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254131 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access